Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by Wall Street Zen

Theravance Biopharma (NASDAQ:TBPH) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “strong-buy” rating in a note issued to investors on Sunday.

Other equities research analysts also recently issued reports about the company. Weiss Ratings raised Theravance Biopharma from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, March 24th. Oppenheimer lowered Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. BTIG Research reaffirmed a “buy” rating and issued a $21.00 target price on shares of Theravance Biopharma in a research report on Friday, March 20th. HC Wainwright lifted their price target on shares of Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Finally, B. Riley Financial reissued a “neutral” rating and issued a $14.00 price target (down from $28.00) on shares of Theravance Biopharma in a report on Wednesday, March 4th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $21.33.

Theravance Biopharma Price Performance

NASDAQ:TBPH opened at $15.26 on Friday. Theravance Biopharma has a one year low of $7.90 and a one year high of $21.03. The company has a fifty day moving average price of $17.40 and a 200 day moving average price of $16.94. The stock has a market cap of $785.74 million, a P/E ratio of 7.52 and a beta of 0.17.

Insider Transactions at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the completion of the transaction, the senior vice president directly owned 232,699 shares in the company, valued at $3,248,478.04. This represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 6.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Theravance Biopharma

Several large investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Theravance Biopharma by 26.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 515 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 781 shares in the last quarter. Creative Planning boosted its position in Theravance Biopharma by 6.7% in the third quarter. Creative Planning now owns 13,450 shares of the biopharmaceutical company’s stock valued at $196,000 after buying an additional 842 shares in the last quarter. State of Wyoming grew its stake in Theravance Biopharma by 5.7% during the second quarter. State of Wyoming now owns 18,928 shares of the biopharmaceutical company’s stock worth $209,000 after buying an additional 1,019 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Theravance Biopharma by 6.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,747 shares of the biopharmaceutical company’s stock worth $174,000 after acquiring an additional 1,020 shares in the last quarter. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.